-+ 0.00%
-+ 0.00%
-+ 0.00%

Incannex wins US patent for IHL-42X obstructive sleep apnea treatment, expiry 2040

PUBT·09/09/2026 11:32:29
Listen to the news
Incannex wins US patent for IHL-42X obstructive sleep apnea treatment, expiry 2040
  • Incannex won a U.S. patent covering the IHL-42X composition and methods of treatment for obstructive sleep apnea.
  • The patent carries a baseline expiry of July 9, 2040.
  • Incannex is assessing eligibility for patent term extension if IHL-42X later wins marketing approval.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incannex Healthcare Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-098213), on September 09, 2026, and is solely responsible for the information contained therein.